Insiders Trades
Klea Holding Stock: price and insider trades · France
1 insider bought €33k of shares over the last 90 days, the latest filed 20 Jul 2026.
Klea Holding: what insiders have been doing
This page follows insider dealings at Klea Holding as filed with AMF, a company from the Healthcare & Pharma sector. 1 insider has disclosed 21 filings since 18 October 2025.
Only purchases show up on the open market, 21 purchases in all worth €471k, filed by 1 insider. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 chief executive. One trade stands out by size: a purchase of €76k from Raphael Smila, disclosed on 4 March 2026, or 0.13% of market capitalisation.
Compared with its exchange (316 companies, median 6 filings), a count of 21 filings is above the norm. Over the whole record (from 2021), the tally stands at 72 purchases and no sales.
In the case of 10 purchases, another manager of the company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster. The most recent open-market purchase was published on 20 July 2026, 89 days ago. Between a trade and the moment it shows up on AMF, the median delay is 1 day. Under the Market Abuse Regulation, managers have three business days to notify their trades.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by AMF. They describe what insiders did and are not a recommendation.
Insider Decl.
74
Thresholds
n/a
Buy Volume
€1M
72 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleRaphael Smila65 buys
Clea Smila1 buy
Sasha Smila1 buy
Since the insiders bought
- -25.6%Entry €0.16 · Close 13 Oct 2026 €0.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Fundamental score
Ranked 3,960 of 24,148 companies
69.0
score / 100
Value74
Quality64
FCF yld10%
Earn yld5.9%
EV/EBITDA8.3x
ROE8.2%
Gross mgn44%
Net mgn10%
Debt/EBITDA1.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€0.12
Analyst consensus
Income statement
Revenue€22.2M
Gross profit€9.8M44% margin
EBITDA€5.3M24% margin
Net income€2.3M10.3% margin
Valuation
PER (trailing)12.0x
P/Book1.3x
Beta-0.45
Balance sheet & cash
Market cap€36.7M
Total debt€5.4M
Free Cash Flow€3.9M
Debt / Equity19%
Profitability & ownership
ROE8.2%
ROA6.1%
% insiders0.0%
% institutions1.0%
Last declaration on 20 July 2026
Declarations74 total
87,000 shares@ €0.1770.036% mcap1.9% of flowActionEuronext Growth ParisISIN FR00134818352026DD1127565
Canonical exit: 14 Oct 2026 (T+90)
103,000 shares@ €0.1740.042% mcap2.2% of flowActionEuronext Growth ParisISIN FR00134818352026DD1127566
Canonical exit: 15 Oct 2026 (T+90)
95,000 shares@ €0.18980.031% mcap2.2% of flowActionEuronext Growth ParisISIN FR00134818352026DD1099718
Canonical exit: 7 Jun 2026 (T+90)
167,212 shares@ €0.19070.055% mcap3.8% of flowActionEuronext Growth ParisISIN FR00134818352026DD1099711
Canonical exit: 7 Jun 2026 (T+90)
40,000 shares@ €0.2020.014% mcap1.0% of flowActionEuronext Growth ParisISIN FR00134818352026DD1099640
Canonical exit: 4 Jun 2026 (T+90)
25,000 shares@ €0.2040.0087% mcap0.6% of flowActionEuronext Growth ParisISIN FR00134818352026DD1099644
Canonical exit: 4 Jun 2026 (T+90)
80,000 shares@ €0.19090.026% mcap45.3% of flowActionEuronext Growth ParisISIN FR00134818352026DD1098784
Canonical exit: 2 Jun 2026 (T+90)
310,000 shares@ €0.18840.10% mcap7.0% of flowActionEuronext Growth ParisISIN FR00134818352026DD1098400
Canonical exit: 1 Jun 2026 (T+90)
400,000 shares@ €0.18930.13% mcap9.1% of flowActionEuronext Growth ParisISIN FR00134818352026DD1098401
Canonical exit: 1 Jun 2026 (T+90)
301,243 shares@ €0.19630.10% mcap7.1% of flowActionEuronext Growth ParisISIN FR00134818352026DD1098004
Canonical exit: 31 May 2026 (T+90)
320,000 shares@ €0.19480.11% mcap7.5% of flowActionEuronext Growth ParisISIN FR00134818352026DD1098038
Canonical exit: 31 May 2026 (T+90)
53,156 shares@ €0.22981.5% of flowActionEuronext Growth ParisISIN FR00134818352025DD1086246
Canonical exit: 23 Mar 2026 (T+90)
79,613 shares@ €0.22752.2% of flowActionEuronext Growth ParisISIN FR00134818352025DD1086247
Canonical exit: 23 Mar 2026 (T+90)
40,000 shares@ €0.24651.2% of flowActionEuronext Growth ParisISIN FR00134818352025DD1071404
Canonical exit: 23 Feb 2026 (T+90)
65,000 shares@ €0.23441.8% of flowActionEuronext Growth ParisISIN FR00134818352025DD1067512
Canonical exit: 2 Feb 2026 (T+90)
5,000 shares@ €0.2460.1% of flowActionEuronext Growth ParisISIN FR00134818352025DD1067513
Canonical exit: 2 Feb 2026 (T+90)
40,000 shares@ €0.242828.8% of flowActionEuronext Growth ParisISIN FR00134818352025DD1067131
Canonical exit: 1 Feb 2026 (T+90)
16,720 shares@ €0.25712.8% of flowActionEuronext Growth ParisISIN FR00134818352025DD1067128
Canonical exit: 26 Jan 2026 (T+90)
20,000 shares@ €0.25250.6% of flowActionEuronext Growth ParisISIN FR00134818352025DD1064485
Canonical exit: 18 Jan 2026 (T+90)
40,000 shares@ €0.25351.2% of flowActionEuronext Growth ParisISIN FR00134818352025DD1064486
Canonical exit: 18 Jan 2026 (T+90)
70,000 shares@ €0.25382.1% of flowActionEuronext Growth ParisISIN FR00134818352025DD1064483
Canonical exit: 14 Jan 2026 (T+90)
50,000 shares@ €0.20451.2% of flowActionEuronext Growth ParisISIN FR00134818352025DD1055928
Canonical exit: 1 Dec 2025 (T+90)
15,000 shares@ €0.2130.4% of flowActionEuronext Growth ParisISIN FR00134818352025DD1055940
Canonical exit: 1 Dec 2025 (T+90)
50,000 shares@ €0.2121.3% of flowActionEuronext Growth ParisISIN FR00134818352025DD1055941
Canonical exit: 1 Dec 2025 (T+90)
15,000 shares@ €0.2050.4% of flowActionEuronext Growth ParisISIN FR00134818352025DD1054448
Canonical exit: 19 Nov 2025 (T+90)
25 of 74 declarations
About Klea Holding
Klea Holding is a listed French group traded on Euronext Growth Paris under ISIN FR0013481835 and ticker ALKLH. The company sits at the crossroads of healthcare, digital services, and investment holding activities. Its origins date back to 2007, when it started out as an innovator in medical devices. Over time, the company has transformed into an international investment and operating holding company, focused on acquiring, developing, and digitizing businesses across several sectors in order to maximize growth and value creation.
Klea Holding’s current strategy is built around a disciplined capital-allocation framework, a relatively low-debt balance sheet, and an experienced governance structure. The group presents itself as a permanent investment and animation holding company, with a reference shareholder that provides stability and continuity. Management emphasizes agility, transparency, and support for subsidiaries, with the stated goal of improving access to financing while maintaining financial flexibility. In practice, this means Klea Holding acts both as an investor and as an active partner to its operating companies.
Read moreShow less
Operationally, the group’s portfolio highlights a clear healthcare and digital-services focus. Its subsidiaries and investments include Smart Salem, Smart Health, and Bewellthy. Smart Salem is associated with digitalized medical diagnostic centers, while Smart Health and Bewellthy are positioned around innovative healthcare solutions, connected health, and teleconsultation. These assets illustrate the company’s emphasis on technology-enabled healthcare services, where digitalization, process efficiency, and patient convenience are core competitive factors.
Geographically, Klea Holding has built an international footprint, with activities in the United Arab Emirates, Saudi Arabia, France, and the broader European Union. This positioning gives the group exposure to markets where demand for digital healthcare, medical screening, and telehealth solutions continues to expand. Recent corporate communications indicate solid momentum, including reported profitable revenue growth of 34% in 2025 at constant exchange rates, underscoring the company’s operational execution. Another notable development is the announcement of Klea Pharmaceuticals in 2026, which points to further diversification within healthcare.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
